1. Home
  2. ALT vs PMO Comparison

ALT vs PMO Comparison

Compare ALT & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • PMO
  • Stock Information
  • Founded
  • ALT 1997
  • PMO 1993
  • Country
  • ALT United States
  • PMO United States
  • Employees
  • ALT N/A
  • PMO N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • PMO Finance Companies
  • Sector
  • ALT Health Care
  • PMO Finance
  • Exchange
  • ALT Nasdaq
  • PMO Nasdaq
  • Market Cap
  • ALT 348.6M
  • PMO 291.4M
  • IPO Year
  • ALT N/A
  • PMO N/A
  • Fundamental
  • Price
  • ALT $4.00
  • PMO $10.36
  • Analyst Decision
  • ALT Strong Buy
  • PMO
  • Analyst Count
  • ALT 7
  • PMO 0
  • Target Price
  • ALT $16.50
  • PMO N/A
  • AVG Volume (30 Days)
  • ALT 2.7M
  • PMO 99.0K
  • Earning Date
  • ALT 11-07-2025
  • PMO 01-01-0001
  • Dividend Yield
  • ALT N/A
  • PMO 4.10%
  • EPS Growth
  • ALT N/A
  • PMO N/A
  • EPS
  • ALT N/A
  • PMO 0.42
  • Revenue
  • ALT $20,000.00
  • PMO N/A
  • Revenue This Year
  • ALT N/A
  • PMO N/A
  • Revenue Next Year
  • ALT N/A
  • PMO N/A
  • P/E Ratio
  • ALT N/A
  • PMO $24.38
  • Revenue Growth
  • ALT N/A
  • PMO N/A
  • 52 Week Low
  • ALT $2.90
  • PMO $8.57
  • 52 Week High
  • ALT $11.16
  • PMO $10.68
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.72
  • PMO 52.62
  • Support Level
  • ALT $3.83
  • PMO $10.36
  • Resistance Level
  • ALT $4.15
  • PMO $10.45
  • Average True Range (ATR)
  • ALT 0.17
  • PMO 0.09
  • MACD
  • ALT 0.00
  • PMO -0.02
  • Stochastic Oscillator
  • ALT 58.90
  • PMO 16.67

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

Share on Social Networks: